Genetic Technologies (AU:GTG) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rhythm Biosciences Ltd has acquired the Genetype genetic risk assessment business, enhancing its oncology portfolio with an immediate revenue stream and growth potential. This strategic acquisition allows Rhythm to leverage Genetype’s expertise and expand its market presence in both Australia and the US. The integration of Genetype’s technology and team is expected to drive accelerated commercial growth and diversification.
For further insights into AU:GTG stock, check out TipRanks’ Stock Analysis page.